Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 7, 2006, to report its financial and operating results for the quarter and nine months ended September 30, 2006. This filing primarily serves to provide investors with the company's performance data, which was announced via a press release issued on November 6, 2006. The key takeaway for investors is that the company has officially disclosed its financial performance for the period. While the 8-K itself does not contain the detailed financial figures, it directs readers to the attached press release (Exhibit 99.1) for these specifics. Investors should refer to this press release to understand Regeneron's revenue, profitability, and operational progress during the third quarter and the first nine months of 2006.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 7, 2006.
- 2The filing reports on the financial and operating results for the quarter and nine months ended September 30, 2006.
- 3The information was initially announced in a press release dated November 6, 2006.
- 4The press release containing the detailed financial and operating results is attached as Exhibit 99.1.
- 5This 8-K filing is made pursuant to Item 2.02 of Form 8-K, focusing on Results of Operations and Financial Condition.